| Title |
Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States
|
|---|---|
| Published in |
Diabetes Therapy, February 2018
|
| DOI | 10.1007/s13300-018-0371-y |
| Pubmed ID | |
| Authors |
Cheryl Neslusan, Anna Teschemaker, Michael Willis, Pierre Johansen, Lien Vo |
| Abstract |
Agents that inhibit sodium glucose co-transporter 2 (SGLT2), including canagliflozin and dapagliflozin, are approved in the United States for the treatment of adults with type 2 diabetes mellitus (T2DM). SGLT2 inhibition lowers blood glucose by increasing urinary glucose excretion, which leads to a mild osmotic diuresis and a net loss of calories that are associated with reductions in body weight and blood pressure. This analysis evaluated the cost-effectiveness of canagliflozin 300 mg versus dapagliflozin 10 mg in patients with T2DM inadequately controlled with metformin in the United States. A 30-year cost-effectiveness analysis was performed using the validated Economic and Health Outcomes Model of T2DM (ECHO-T2DM) from the perspective of the third-party health care system in the United States. Patient demographics, biomarker values, and treatment effects for the ECHO-T2DM model were sourced primarily from a network meta-analysis (NMA) that included studies of canagliflozin and dapagliflozin in patients with T2DM on background metformin. Costs were derived from sources specific to the United States. Outcomes and costs were discounted at 3%. Sensitivity analyses that varied key model parameters were conducted. Canagliflozin 300 mg dominated dapagliflozin 10 mg as an add-on to metformin over 30 years, with an estimated cost offset of $13,991 and a quality-adjusted life-year gain of 0.08 versus dapagliflozin 10 mg. Results were driven by the better HbA1c lowering achieved with canagliflozin, which translated to less need for insulin rescue therapy. Findings from sensitivity analyses were consistent with the base case. These results suggest that canagliflozin 300 mg is likely to provide better health outcomes at a lower overall cost than dapagliflozin 10 mg in patients with T2DM inadequately controlled with metformin from the perspective of the United States health care system. Janssen Scientific Affairs, LLC and Janssen Global Services, LLC. |
X Demographics
The data shown below were collected from the profiles of 20 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 12 | 60% |
| Chile | 1 | 5% |
| Unknown | 7 | 35% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 14 | 70% |
| Practitioners (doctors, other healthcare professionals) | 4 | 20% |
| Scientists | 1 | 5% |
| Science communicators (journalists, bloggers, editors) | 1 | 5% |
Mendeley readers
The data shown below were compiled from readership statistics for 66 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 66 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 8 | 12% |
| Student > Bachelor | 8 | 12% |
| Researcher | 7 | 11% |
| Student > Ph. D. Student | 7 | 11% |
| Other | 5 | 8% |
| Other | 10 | 15% |
| Unknown | 21 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 19 | 29% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 11% |
| Nursing and Health Professions | 6 | 9% |
| Biochemistry, Genetics and Molecular Biology | 3 | 5% |
| Economics, Econometrics and Finance | 3 | 5% |
| Other | 8 | 12% |
| Unknown | 20 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 February 2018.
All research outputs
#2,230,274
of 23,020,670 outputs
Outputs from Diabetes Therapy
#80
of 1,038 outputs
Outputs of similar age
#55,170
of 437,329 outputs
Outputs of similar age from Diabetes Therapy
#4
of 35 outputs
Altmetric has tracked 23,020,670 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,038 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.4. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 437,329 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 35 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.